We have located links that may give you full text access.
Journal Article
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.
Stimulation of matrix metalloprotease 3 release from human chondrocytes by the interaction of stromal cell-derived factor 1 and CXC chemokine receptor 4.
Arthritis and Rheumatism 2002 January
OBJECTIVE: The chemokine family of secreted proteins regulates cellular activities through interaction with G protein-coupled chemokine receptors. The aim of this study was to analyze the role of a chemokine stromal cell-derived factor 1 (SDF-1) and its receptor CXCR4 in rheumatoid arthritis (RA) and osteoarthritis (OA) by examining their gene expression in joint cartilage and synovium and by determining the effect of their interaction on the release of matrix metalloproteases (MMPs) from chondrocytes.
METHODS: SDF-1 protein levels in synovial fluid from the knee joints of 58 RA patients, 55 OA patients, and 60 control patients without arthritis were quantified by enzyme-linked immunosorbent assay. SDF-1 and CXCR4 messenger RNA (mRNA) levels in chondrocytes and synovial fibroblasts were determined by reverse transcriptase-polymerase chain reaction. Isolated human chondrocytes were stimulated with 100 ng/ml of SDF-1, and the response was analyzed by quantifying the release of MMPs 1 and 3.
RESULTS: We found that the concentration of SDF-1 in synovial fluid increased 3.57-fold in OA patients and 10.71-fold in RA patients compared with normal controls. The source of SDF-1 in synovial fluid was synovium, since SDF-1 mRNA was synthesized by synovial fibroblasts but not by chondrocytes. Conversely, CXCR4 was expressed by chondrocytes but not by synovial fibroblasts. The interaction of SDF-1, which was abundant in synovial fluid from RA and OA patients, with CXCR4-positive chondrocytes resulted in a specific elevation of the release of the cartilage matrix-degrading enzyme MMP-3 (stromelysin 1).
CONCLUSION: Our findings suggest a novel mechanism by which synovial cells induce degradation of cartilage matrix through SDF-1 signaling in RA and OA.
METHODS: SDF-1 protein levels in synovial fluid from the knee joints of 58 RA patients, 55 OA patients, and 60 control patients without arthritis were quantified by enzyme-linked immunosorbent assay. SDF-1 and CXCR4 messenger RNA (mRNA) levels in chondrocytes and synovial fibroblasts were determined by reverse transcriptase-polymerase chain reaction. Isolated human chondrocytes were stimulated with 100 ng/ml of SDF-1, and the response was analyzed by quantifying the release of MMPs 1 and 3.
RESULTS: We found that the concentration of SDF-1 in synovial fluid increased 3.57-fold in OA patients and 10.71-fold in RA patients compared with normal controls. The source of SDF-1 in synovial fluid was synovium, since SDF-1 mRNA was synthesized by synovial fibroblasts but not by chondrocytes. Conversely, CXCR4 was expressed by chondrocytes but not by synovial fibroblasts. The interaction of SDF-1, which was abundant in synovial fluid from RA and OA patients, with CXCR4-positive chondrocytes resulted in a specific elevation of the release of the cartilage matrix-degrading enzyme MMP-3 (stromelysin 1).
CONCLUSION: Our findings suggest a novel mechanism by which synovial cells induce degradation of cartilage matrix through SDF-1 signaling in RA and OA.
Full text links
Related Resources
Trending Papers
Challenges in Septic Shock: From New Hemodynamics to Blood Purification Therapies.Journal of Personalized Medicine 2024 Februrary 4
Molecular Targets of Novel Therapeutics for Diabetic Kidney Disease: A New Era of Nephroprotection.International Journal of Molecular Sciences 2024 April 4
The 'Ten Commandments' for the 2023 European Society of Cardiology guidelines for the management of endocarditis.European Heart Journal 2024 April 18
A Guide to the Use of Vasopressors and Inotropes for Patients in Shock.Journal of Intensive Care Medicine 2024 April 14
Diagnosis and Management of Cardiac Sarcoidosis: A Scientific Statement From the American Heart Association.Circulation 2024 April 19
Essential thrombocythaemia: A contemporary approach with new drugs on the horizon.British Journal of Haematology 2024 April 9
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app